Xilio Therapeutics, Inc.
http://www.xiliotx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Xilio Therapeutics, Inc.
Deal Watch: Gilead Acquires Xilio’s IL-12 Activating Candidate
Plus deals involving Avalo/AlmataBio, AbbVie/Parvus, NovaBay/Eyenovia, Bayer/Aignostics, Merck & Co./Pearl, tech transfer agreements and deals in brief.
Nektar/BMS’s IL-2 Inhibitor Melanoma Failure Leaves Room For Other Contenders
Nektar is hoping the combination of bempegaldesleukin and Opdivo could have better chances in kidney and bladder cancers, but analysts aren’t sure and see other IL-2 therapeutics as having better prospects.
Merck KGaA's M Ventures Moving On Up With €600m Boost
The new capital will allow the VC arm to create and finance "a new and larger portfolio of innovative companies that align with the future strategies" of Merck's businesses.
Finance Watch: Four New IPOs Hold Steady In First Days Of Trading
Public Company Edition: Xilio, Ventyx, MiNK and Context went public in the US and later traded at or above their initial public offering prices. Also, Sarepta raised $500m and Relay grossed $350m in new offerings, while Oncopeptides, Esperion, Zymergen and Ardelyx reorganized and cut jobs.
Company Information
- Industry
-
Pharmaceuticals
- Vaccines
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- Akrevia Therapeutics
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice